Her scientific interests lie mostly in Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Transplantation. Her biological study spans a wide range of topics, including Immunology and Oncology. As a part of the same scientific family, Suzanne R. Hayman mostly works in the field of Multiple myeloma, focusing on Dexamethasone and, on occasion, Corticosteroid and Combination therapy.
Her work deals with themes such as Hematology and Urology, which intersect with Surgery. Her studies in Gastroenterology integrate themes in fields like Refractory, Neutropenia, Pathology, Hazard ratio and Survival analysis. Her Transplantation study integrates concerns from other disciplines, such as Beta-2 microglobulin, Chemotherapy, Stem cell, POEMS syndrome and Organomegaly.
Her main research concerns Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Oncology. Her study in Transplantation, Lenalidomide, Amyloidosis, Autologous stem-cell transplantation and AL amyloidosis falls within the category of Internal medicine. Her work carried out in the field of Transplantation brings together such families of science as Survival analysis and Stem cell.
Her work is dedicated to discovering how Multiple myeloma, Dexamethasone are connected with Cyclophosphamide and other disciplines. Her study in Gastroenterology is interdisciplinary in nature, drawing from both Progression-free survival, Hematology, Primary systemic amyloidosis, Very Good Partial Response and Hazard ratio. The study incorporates disciplines such as Newly diagnosed and Clinical trial in addition to Oncology.
Her primary areas of investigation include Internal medicine, Multiple myeloma, Oncology, Amyloidosis and AL amyloidosis. In her study, Progression-free survival is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine. Her Multiple myeloma research is multidisciplinary, incorporating perspectives in Newly diagnosed, Survival analysis, Bone marrow and Hazard ratio.
Her Oncology study also includes
Suzanne R. Hayman spends much of her time researching Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Amyloidosis. Internal medicine is closely attributed to Oncology in her research. Her Multiple myeloma study focuses on Lenalidomide in particular.
Her Gastroenterology study also includes fields such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy.
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz.
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri.
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar;Angela Dispenzieri;Martha Q. Lacy;Suzanne R. Hayman.
Journal of Clinical Oncology (2012)
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
S. Vincent Rajkumar;Suzanne Hayman;Morie A. Gertz;Angela Dispenzieri.
Journal of Clinical Oncology (2002)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli.
Mayo Clinic Proceedings (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy;Suzanne R. Hayman;Morie A. Gertz;Angela Dispenzieri.
Journal of Clinical Oncology (2009)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
S Kumar;A Dispenzieri;M Q Lacy;S R Hayman.
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Angela Dispenzieri;Martha Q. Lacy;Steven R. Zeldenrust;Suzanne R. Hayman.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Martha Q. Lacy;Angela Dispenzieri;Morie A. Gertz;Philip R. Greipp.
Mayo Clinic Proceedings (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: